AUPH News and Press, Aurinia Pharmaceuticals Inc From 08/24/22

Summary Today, we circle back on biopharma name Aurinia Pharmaceuticals for the first time since last September. The company has been the subject of many takeover rumors, is seeing good revenue growth, but has some litigation worries at the moment. An investment analysis follo...

LUPKYNIS revenues and company net losses are tracking better than my valuation model predicts -- and new European revenues are on the horizon. However, expenses continue to rise, which is contrary to my modelling. Overshadowing all of this are severe patent risks. This a...

Aurinia Pharmaceuticals Inc. (AUPH) Q2 2022 Earnings Conference Call August 04, 2022 8:30 AM ET Company Participants DeDe Sheel – Vice President-Investor Relations Peter Greenleaf – President and Chief Executive Officer Joe Miller – Chief Fin...

Shares of commercial-stage autoimmune disease specialist Aurinia Pharmaceuticals (NASDAQ: AUPH) raced higher in early action Thursday morning, rising as much as 15.7%. However, Aurinia's shares have given back most of these gains as the session has progressed. As of 10:58 a.m. E...

Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH ) slipped in the pre-market Thursday after reporting a mixed financial performance for 2Q 2022 despite a sales recovery in the company’s lupus nephritis drug Lupkynis. Net revenue for the quarter more than quadru...

Aurinia Pharma press release ( NASDAQ: AUPH ): Q2 GAAP EPS of -$0.25 misses by $0.03 . Revenue of $28.2M (+326.0% Y/Y) beats by $1.16M . Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS (voclosporin) for 2022 For furth...

Net revenue increased to $28.2 million for Q2 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS ® (voclosporin) for 2022 Continued increases in LUPKYNIS Patients on Treatment; Steady Conversion Rates and Payor Coverage EMA ...

Aurinia Pharma ( NASDAQ: AUPH ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.22 (+40.5% Y/Y) and the consensus Revenue Estimate is $27.04M (+308.5% Y/Y). Over the last 3 months, EPS estimate...

ABMD , ABUS , ACIW , ADAP , OTCQX:ADDYY , ADT , AG , AGIO , AHH , APD , APO , APTV , ARW , ATI , AUPH , AUTL , AZEK , BABA , BALL , BALY , OTCPK:BAYZF , BCE , BCRX , BDX , BKI , CBRE , ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings for companies due to report...